BioCryst Reports Third Quarter 2023 Financial Results and Provides Business Update
02 nov. 2023 07h00 HE
|
BioCryst Pharmaceuticals, Inc.
- Q3 2023 ORLADEYO net revenue of $85.7 million (+29.8 percent y-o-y) -- - Company expects to achieve no less than $320 million in full year 2023 ORLADEYO revenue and $1 billion in peak ORLADEYO...
BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
27 oct. 2023 07h00 HE
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 27, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present two abstracts on oral, once-daily...
BioCryst Begins Enrollment in Proof-of-Concept Trial to Confirm Safe, Effective, Once-daily Dose of Oral Factor D Inhibitor, BCX10013
26 oct. 2023 07h00 HE
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 26, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in a proof-of-concept clinical trial...
BioCryst to Host R&D Day on November 3
20 oct. 2023 07h00 HE
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will host an R&D Day at 1:00 p.m. ET on Friday,...
BioCryst to Report Third Quarter 2023 Financial Results on November 2
19 oct. 2023 07h00 HE
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 19, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2023 financial results...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 oct. 2023 07h00 HE
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 04, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted...
L’INESSS recommande le remboursement public pour ORLADEYO® (bérotralstat) de BioCryst pour la prévention des crises chez les patients atteints d’angio-oedème héréditaire au Québec
18 sept. 2023 07h00 HE
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., 18 sept. 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq : BCRX) a annoncé aujourd’hui que l’Institut national d’excellence en santé et services sociaux...
INESSS Recommends Public Reimbursement for BioCryst’s ORLADEYO® (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in Québec
18 sept. 2023 07h00 HE
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Sept. 18, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Institut national d'excellence en santé et services sociaux...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 sept. 2023 07h00 HE
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors...
BioCryst to Present at Upcoming Investor Conferences
23 août 2023 16h01 HE
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Aug. 23, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 2023 Wells Fargo Healthcare...